Nutrition Research and Practice

The Korean Nutrition Society (한국영양학회)
권호 표지
DOI QR코드

DOI QR Code

Active hexose correlated compound potentiates the antitumor effects of low-dose 5-fluorouracil through modulation of immune function in hepatoma 22 tumor-bearing mice

  • Cao, Zhiyun (Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine) ;
  • Chen, Xuzheng (Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine) ;
  • Lan, Lan (The Second People's Hospital of Fujian Province) ;
  • Zhang, Zhideng (Inspection and Quarantine Technique Centre of Fujian Entry-exit Inspection and Quarantine Bureau) ;
  • Du, Jian (The Second People's Hospital of Fujian Province) ;
  • Liao, Lianming (Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine)
  • Received : 2014.05.07
  • Accepted : 2014.09.23
  • Published : 2015.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

BACKGROUND/OBJECTIVES: A variety of immunomodulators can improve the efficacy of low-dose chemotherapeutics. Active hexose correlated compound (AHCC), a mushroom mycelia extract, has been shown to be a strong immunomodulator. Whether AHCC could enhance the antitumor effect of low-dose 5-fluorouracil (5-FU) via regulation of host immunity is unknown. MATERIALS/METHODS: In the current study Hepatoma 22 (H22) tumor-bearing mice were treated with PBS, 5-FU ($10mg{\cdot}kg^{-1}{\cdot}d^{-1}$, i.p), or AHCC ($360mg{\cdot}kg^{-1}{\cdot}d^{-1}$, i.g) plus 5-FU, respectively, for 5 d. $CD^{3+}$, $CD^{4+}$, $CD^{8+}$, and NK in peripheral blood were detected by flow cytometry. ALT, AST, BUN, and Cr levels were measured by biochemical assay. IL-2 and $TNF{\alpha}$ in serum were measured using the RIA kit and apoptosis of tumor was detected by TUNEL staining. Bax, Bcl-2, and TS protein levels were measured by immunohistochemical staining and mRNA level was evaluated by RT-PCR. RESULTS: Diet consumption and body weight showed that AHCC had no apparent toxicity. AHCC could reverse liver injury and myelosuppression induced by 5-FU (P < 0.05). Compared to mice treated with 5-FU, mice treated with AHCC plus 5-FU had higher thymus index, percentages of $CD^{3+}$, $CD^{4+}$, and NK cells (P < 0.01), and ratio of $CD^{4+}$/$CD^{8+}$ (P < 0.01) in peripheral blood. Radioimmunoassay showed that mice treated with AHCC plus 5-FU had the highest serum levels of IL-2 and $TNF{\alpha}$ compared with the vehicle group and 5-FU group. More importantly, the combination of AHCC and 5-FU produced a more potent antitumor effect (P < 0.05) and caused more severe apoptosis in tumor tissue (P < 0.05) compared with the 5-FU group. In addition, the combination of AHCC and 5-FU further up-regulated the expression of Bcl-2 associated X protein (Bax) (P < 0.01), while it down-regulated the expression of B cell lymphoma 2 (Bcl-2) (P < 0.01). CONCLUSIONS: These results support the claim that AHCC might be beneficial for cancer patients receiving chemotherapy.

Keywords

References

  1. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000;5:4-27.
  2. Burikhanov RB, Wakame K, Igarashi Y, Wang S, Matsuzaki S. Suppressive effect of active hexose correlated compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat. Endocr Regul 2000;34:181-8.
  3. Aviles H, Belay T, Vance M, Sun B, Sonnenfeld G. Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloading model of spaceflight conditions. J Appl Physiol (1985) 2004;97:1437-44. https://doi.org/10.1152/japplphysiol.00259.2004
  4. Uno K, Kosuna K, Sun B, Fujii H, Wakame K, Chikumaru S, Hosokawa G, Ueda Y. Active hexose correlated compound (AHCC) improves immunological parameters and performance status of patients with solid tumors. Biotherapy (Tokyo) 2000;14:303-9.
  5. Aviles H, O'Donnell P, Orshal J, Fujii H, Sun B, Sonnenfeld G. Active hexose correlated compound activates immune function to decrease bacterial load in a murine model of intramuscular infection. Am J Surg 2008;195:537-45. https://doi.org/10.1016/j.amjsurg.2007.05.045
  6. Nogusa S, Gerbino J, Ritz BW. Low-dose supplementation with active hexose correlated compound improves the immune response to acute influenza infection in C57BL/6 mice. Nutr Res 2009;29: 139-43. https://doi.org/10.1016/j.nutres.2009.01.005
  7. Ritz BW, Nogusa S, Ackerman EA, Gardner EM. Supplementation with active hexose correlated compound increases the innate immune response of young mice to primary influenza infection. J Nutr 2006;136:2868-73. https://doi.org/10.1093/jn/136.11.2868
  8. Wang S, Welte T, Fang H, Chang GJ, Born WK, O'Brien RL, Sun B, Fujii H, Kosuna K, Wang T. Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice. J Nutr 2009;139:598-602. https://doi.org/10.3945/jn.108.100297
  9. Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, Kwon AH, Kamiyama Y. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol 2002;37:78-86. https://doi.org/10.1016/S0168-8278(02)00091-0
  10. Cowawintaweewat S, Manoromana S, Sriplung H, Khuhaprema T, Tongtawe P, Tapchaisri P, Chaicumpa W. Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol 2006; 24:33-45.
  11. Casale F, Canaparo R, Serpe L, Muntoni E, Pepa CD, Costa M, Mairone L, Zara GP, Fornari G, Eandi M. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 2004;50:173-9. https://doi.org/10.1016/j.phrs.2004.01.006
  12. Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA, Robertson JM. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002;52:176-83. https://doi.org/10.1016/S0360-3016(01)01820-X
  13. Dencausse Y, Sturm J, Hartung G, Dietzler P, Edler L, Bambach M, Wojatschek C, Lindemann H, Qeisser W. Adjuvant radio-chemotherapy in stage II-III rectal cancer with 24-hour infusion of highdose 5-fluorouracil and folinic acid: evaluation of feasibility. Onkologie 2001;24:476-80. https://doi.org/10.1159/000055129
  14. Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG, Sorensen JM, Chen AP, Goldstein L, Jordan E, Setser A, Goldspiel B, DeCarvalho M, Allegra CJ. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-Laspartate in metastatic gastrointestinal adenocarcinoma. Cancer Res 1993;53:4828-36.
  15. Kobayashi R, Yoshimatsu K, Yokomizo H, Katsube T, Ogawa K. Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity. Anticancer Res 2007;27:675-9.
  16. Yoshimatsu K, Yokomizo H, Fujimoto T, Umehara A, Otani T, Matsumoto A, Osawa G, Shiozawa S, Katsube T, Naritaka Y, Ogawa K. First-line chemotherapy with low-dose leucovorin plus 5-fluorouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer. Anticancer Res 2007;27:1641-4.
  17. Butterfield LH, Ribas A. Immunotherapy of hepatocellular carcinoma. Expert Opin Biol Ther 2002;2:123-33. https://doi.org/10.1517/14712598.2.2.123
  18. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010;28:3994-4005. https://doi.org/10.1200/JCO.2010.28.7805
  19. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004;5:409-18. https://doi.org/10.1016/S1470-2045(04)01508-6
  20. Ganne-Carrie N, Trinchet JC. Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004;16:275-81.
  21. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42. https://doi.org/10.1053/jhep.2003.50047
  22. Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon ${\alpha}$-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2012;118:3302-10. https://doi.org/10.1002/cncr.26648
  23. Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Tomimaru Y, Osuga K, Umeshita K, Doki Y, Mori M. Long-term outcome of combined interferon-${\alpha}$ and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 2011;80:63-9. https://doi.org/10.1159/000328281
  24. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H, Kobayashi S, Marubashi S, Takeda Y, Dono K, Umeshita K, Matsuura N, Matsubara K, Doki Y, Mori M, Monden M. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009;100:1647-58. https://doi.org/10.1038/sj.bjc.6605064
  25. Wada H, Nagano H, Yamamoto H, Noda T, Murakami M, Kobayashi S, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer 2009;9:361. https://doi.org/10.1186/1471-2407-9-361
  26. Yin H, Xie F, Zhang J, Yang Y, Deng B, Sun J, Wang Q, Qu X, Mao H. Combination of interferon-${\alpha}$ and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. Cancer Lett 2011;306:34-42. https://doi.org/10.1016/j.canlet.2011.02.017
  27. Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E; FAIT Research Group. 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Hepatol Res 2012;42:150-65. https://doi.org/10.1111/j.1872-034X.2011.00905.x
  28. Ghoneum M, Wimbley M, Salem F, McKlain A, Attallah N, Gill G. Immu-nomodulatory and anticancer effects of active hexose correlated compound (AHCC). Int J Immunother 1995;11:23-8.
  29. Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol 2007;222:152-8. https://doi.org/10.1016/j.taap.2007.03.031
  30. Shigama K, Nakaya A, Wakame K, Nishioka H, Fujii H. Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice. J Exp Ther Oncol 2009;8:43-51.
  31. Sun B, Wakame K, Sato E, Nishioka H, Aruoma OI, Fujii H. The effect of active hexose correlated compound in modulating cytosine arabinoside-induced hair loss, and 6-mercaptopurine- and methotrexate-induced liver injury in rodents. Cancer Epidemiol 2009;33: 293-9. https://doi.org/10.1016/j.canep.2009.07.006
  32. Hunter RJ, Fujii H, Wakame K, Gaikwad A, Wolf JK, Smith JA. Evaluation of active hexose correlated compound (AHCC) in combination with pegylated liposomal doxorubicin for treatment of ovarian cancer. Int J Appl Res Nat Prod 2011;4:6-14.
  33. Fujii H, Nishioka N, Simon RR, Kaur R, Lynch B, Roberts A. Genotoxicity and subchronic toxicity evaluation of Active Hexose Correlated Compound (AHCC). Regul Toxicol Pharmacol 2011;59: 237-50. https://doi.org/10.1016/j.yrtph.2010.10.006
  34. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-74. https://doi.org/10.1146/annurev.immunol.23.021704.115526
  35. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193:1007-8. https://doi.org/10.1126/science.181845
  36. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76. https://doi.org/10.1126/science.3131876
  37. Dillman RO. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother 1994;9:183-209. https://doi.org/10.1089/cbr.1994.9.183
  38. Ferrante A. Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors. Immunol Ser 1992;57:417-36.
  39. Zhu HG, Zollner TM, Klein-Franke A, Anderer FA. Activation of human monocyte/macrophage cytotoxicity by IL-2/IFN gamma is linked to increased expression of an antitumor receptor with specificity for acetylated mannose. Immunol Lett 1993;38:111-9. https://doi.org/10.1016/0165-2478(93)90175-2
  40. Ibayashi Y, Tokuda Y, Saks ER, Sarna GP, Golub SH. In vivo and in vitro activation of NK cytotoxicity with IL-2. Prog Clin Biol Res 1987;244:275-85.
  41. Chatzidakis I, Mamalaki C. T cells as sources and targets of TNF: implications for immunity and autoimmunity. Curr Dir Autoimmun 2010;11:105-18. https://doi.org/10.1159/000289200
  42. Yagita A, Maruyama S, Wakasugi S, Sukegawa Y. H-2 haplotypedependent serum IL-12 production in tumor-bearing mice treated with various mycelial extracts. In Vivo 2002;16:49-54.
  43. Yin Z, Fujii H, Walshe T. Effects of active hexose correlated compound on frequency of CD4+ and CD8+ T cells producing interferon-${\gamma}$ and/or tumor necrosis factor-${\alpha}$ in healthy adults. Hum Immunol 2010;71:1187-90. https://doi.org/10.1016/j.humimm.2010.08.006
  44. Daddaoua A, Martinez-Plata E, Lopez-Posadas R, Vieites JM, Gonzalez M, Requena P, Zarzuelo A, Suarez MD, de Medina FS, Martinez-Augustin O. Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis. J Nutr 2007;137:1222-8. https://doi.org/10.1093/jn/137.5.1222
  45. Li JH, Rosen D, Ronen D, Behrens CK, Krammer PH, Clark WR, Berke G. The regulation of CD95 ligand expression and function in CTL. J Immunol 1998;161:3943-9.
  46. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100. https://doi.org/10.1038/83416

Cited by

  1. Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells vol.12, pp.7, 2017, https://doi.org/10.1371/journal.pone.0181729
  2. MicroRNA signature in the chemoprevention of functionally-enriched stem and progenitor pools (FESPP) by Active Hexose Correlated Compound (AHCC) vol.18, pp.10, 2017, https://doi.org/10.1080/15384047.2017.1373211
  3. Bioactive Immunomodulatory Compounds: A Novel Combinatorial Strategy for Integrated Medicine in Oncology? BAIC Exposure in Cancer Cells vol.18, pp.None, 2015, https://doi.org/10.1177/1534735419866908
  4. The Effects of AHCC®, a Standardized Extract of Cultured Lentinura edodes Mycelia, on Natural Killer and T Cells in Health and Disease: Reviews on Human and Animal Studies vol.2019, pp.None, 2015, https://doi.org/10.1155/2019/3758576
  5. A standardized extract of cultured Lentinula edodes mycelia downregulates cortactin in gemcitabine‑resistant pancreatic cancer cells vol.22, pp.3, 2021, https://doi.org/10.3892/ol.2021.12915
  6. Phytochemicals as an Alternative or Integrative Option, in Conjunction with Conventional Treatments for Hepatocellular Carcinoma vol.13, pp.22, 2015, https://doi.org/10.3390/cancers13225753